Table 1. Clinicopathological characteristics of 129 CSCC patients and their association with Aurora kinase A (AURKA) IHC intensity.

Clinicopathological features	NO	AURKA IHC		χ2	P
		High(++,+++)	Low(-,+)
ECOG performance status
(0,1)	87	49	38	0.010	0.919
(2,3)	42	24	18
Age (y)
<50	55	29	26	0.340	0.560
≥50	74	44	30
Stage
II	61	37	24	0.497	0.481
III	68	36	32
Lymph nodes metastases
No	70	28	42	15.701	0.000
Yes	59	45	14
Differentiation
Well-moderate	62	39	23	1.474	0.225
Poor	67	34	33
Tumor size
≥5.7cm	83	64	19	39.894	0.000
<5.7cm	46	9	37
SCC-ag level (ng/ml)
<2	48	24	24	1.352	0.509
2-10	53	32	21
<10	28	17	11
Hb level (g/dl)
<10	35	25	10	4.306	0.038
≥10	94	48	46
Treatment
Radiation	55	34	21	0.728	0.393
Concurrent Chemoradiation	74	39	35
Recurrence events
Yes	58	49	9	31.345	0.000
No	71	24	47